MODIFICATION
Q -- Antimicrobial Susceptibility Testing
- Notice Date
- 7/15/2011
- Notice Type
- Modification/Amendment
- NAICS
- 621511
— Medical Laboratories
- Contracting Office
- Department of Health and Human Services, Centers for Disease Control and Prevention, Procurement and Grants Office (Atlanta), 2920 Brandywine Road, Room 3000, Atlanta, Georgia, 30341-4146
- ZIP Code
- 30341-4146
- Solicitation Number
- 2011-Q-13591
- Archive Date
- 8/23/2011
- Point of Contact
- Maria S Shamburger,
- E-Mail Address
-
HEG9@cdc.gov
(HEG9@cdc.gov)
- Small Business Set-Aside
- N/A
- Description
- CDC, in collaboration with several state health departments, conducts population-based, laboratory-based surveillance for invasive disease caused by Streptococcus pneumoniae, group A streptococcus (GAS), and group B streptococcus (GBS) through the Active Bacterial Core surveillance (ABCs) program of CDC's Emerging Infections Program Network. ABCs is used to follow trends in disease rates, to assess the effectiveness of public health interventions (e.g., vaccination), and to conduct special epidemiologic and laboratory studies. As a result, timely susceptibility testing and shipping to CDC of these pathogens is an integral function of ABCs. CDC has a requirement for a contractor to conduct antimicrobial susceptibility testing on 1500-3000 pneumococci each year. The precise number cannot be predicted because future disease trends cannot be predicted. Up to 3000 additional isolates of group A and B Streptococcus may also require testing though, again, this number cannot be predicted with certainty. The contractor will then ship in a timely fashion all isolates to CDC for additional testing. Because ABCs conducts numerous special studies of antimicrobial resistance and vaccine impact, testing and shipping of isolates and electronic submission of susceptibility data at least monthly is critical. ABCs data is used by investigators external to CDC; as well as, international partners, including ministries of health, to formulate policies regarding treatment recommendations and vaccine programs. Therefore, strict adherence to Clinical Laboratory Standards Institute (CLSI) guidelines is expected. The Contractor is required to perform the following: 1. Confirm identification of isolates as Streptococcus pneumoniae, GAS, or GBS. 2. Store all isolates in a manner that will ensure future viability. The isolates will be received from the CDC Streptococcal laboratory or directly from surveillance sites collaborating with CDC. Isolates received from surveillance sites then need to be shipped to CDC for additional characterization, e.g., serotyping. 3. Ship additional subcultures of each isolate to the CDC and ATSDR Specimen Packaging, Inventory and Repository (CASPIR) for permanent storage. 4. Perform antimicrobial susceptibility testing of S. pneumoniae, GAS, and GBS as outlined below in the scope of work. This is a full and open competition. The NAICS code for this procurement is 62511. A firm fixed price contract in accordance with FAR part 15 is contemplated. There will be a base period of twelve (12) months and four 12-month option periods. CDC will consider all responsible sources responding to this Request for Proposal (RFP). The RFP number 2011-Q-13591 will be available on or about July 7, 2011. The due date for receipt of proposals will be 8/8/2011. All questions about the RFP shall be submitted via email to heg9@cdc.gov. The complete solicitation package will be available and posted on fbo.gov for downloading when issued. No telephone request of the solicitation will be accepted.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/CDCP/PGOA/2011-Q-13591/listing.html)
- Place of Performance
- Address: TBD, United States
- Record
- SN02501007-W 20110717/110715235937-c6b2091e4af2c2c9587ffbad794dddb7 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |